SR9009

SR9009 (CAS No.: 1379686-30-2) is a synthetic small-molecule REV-ERBα/β agonist widely used in chemical biology and metabolic research to modulate circadian rhythm and energy homeostasis pathways. By selectively activating the nuclear receptors REV-ERBα and REV-ERBβ, SR9009 enhances transcriptional repression of clock-controlled genes, thereby influencing circadian regulation and downstream metabolic processes. It exhibits activity in the nanomolar range, with reported half-maximal inhibitory concentrations of approximately 670 nM and 800 nM for REV-ERBα and REV-ERBβ, respectively, reflecting potent engagement of these targets. In preclinical models, SR9009 has been shown to alter the expression patterns of core clock genes in the hypothalamus and peripheral metabolic tissues, including liver, skeletal muscle, and adipose tissue, leading to increased energy expenditure and modulation of lipid and glucose metabolism. Functional studies in animal models have demonstrated reductions in fat mass and improvements in dyslipidemia and hyperglycemia following repeated administration, highlighting its utility in investigating metabolic disorders and circadian biology. SR9009 is commonly employed in cell-based assays and in vivo studies to probe REV-ERB-mediated signaling pathways, with experimental concentrations or dosing regimens varying depending on specific study designs and research objectives.